These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 2574303)

  • 21. Evidence for an abnormal peripherally mediated vascular response to temperature in Raynaud's phenomenon.
    Walmsley D; Goodfield MJ
    Br J Rheumatol; 1990 Jun; 29(3):181-4. PubMed ID: 2357499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Postocclusive reactive hyperemia in hand-arm vibration syndrome.
    Stoyneva Z
    Int J Occup Med Environ Health; 2016; 29(4):659-66. PubMed ID: 27443761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potent vasodilator activity of calcitonin gene-related peptide in human skin.
    Brain SD; Tippins JR; Morris HR; MacIntyre I; Williams TJ
    J Invest Dermatol; 1986 Oct; 87(4):533-6. PubMed ID: 2428885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The origin of Raynaud's phenomenon.
    Nielubowicz J; Zajaç S; Szamowska R; Adamski M
    J Cardiovasc Surg (Torino); 1978; 19(6):607-14. PubMed ID: 739033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hand warming as a treatment for Raynaud's phenomenon in systemic sclerosis.
    Goodfield MJ; Rowell NR
    Br J Dermatol; 1988 Nov; 119(5):643-6. PubMed ID: 3207617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Laser-Doppler flowmetry in the assessment of "mild" Raynaud's phenomenon and its treatment.
    Cesarone MR; Laurora G; Smith SR; Belcaro G
    Panminerva Med; 1990; 32(4):151-4. PubMed ID: 2090987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms of Raynaud's disease.
    Cooke JP; Marshall JM
    Vasc Med; 2005 Nov; 10(4):293-307. PubMed ID: 16444858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of intra-arterial ketanserin in Raynaud's phenomenon assessed by 99MTc-pertechnetate scintigraphy.
    Kunnen JJ; Dahler HP; Doorenspleet JG; van Oene JC
    Eur J Clin Pharmacol; 1988; 34(3):267-71. PubMed ID: 2840293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathogenesis of Raynaud's phenomenon.
    Herrick AL
    Rheumatology (Oxford); 2005 May; 44(5):587-96. PubMed ID: 15741200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calcitonin gene-related peptide-targeting drugs and Raynaud's phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database.
    Gérard AO; Merino D; Van Obberghen EK; Rocher F; Destere A; Lantéri-Minet M; Drici MD
    J Headache Pain; 2022 May; 23(1):53. PubMed ID: 35505285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
    Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
    BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Calcitonin gene-related peptide (CGRP) causes redistribution of blood flow in humans.
    Jäger K; Muench R; Seifert H; Beglinger C; Bollinger A; Fischer JA
    Eur J Clin Pharmacol; 1990; 39(5):491-4. PubMed ID: 2076743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Raynaud's phenomenon, laser Doppler, isothermal chamber. Exploration of normal and pathologic subjects].
    Boccalon H; Ginestet-Venerandi MC; Puel P
    J Mal Vasc; 1985; 10(1):11-6. PubMed ID: 3156940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathophysiological classification of Raynaud's phenomenon.
    Nilsen KH
    Br J Dermatol; 1980 Jan; 102(1):1-5. PubMed ID: 7378276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nitric oxide-dependent release of vasodilator quantities of calcitonin gene-related peptide from capsaicin-sensitive nerves in rabbit skin.
    Hughes SR; Brain SD
    Br J Pharmacol; 1994 Feb; 111(2):425-30. PubMed ID: 8004386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparative study of the ability of calcitonin gene-related peptide and adrenomedullin(13 - 52) to modulate microvascular but not thermal hyperalgesia responses.
    Chu DQ; Choy M; Foster P; Cao T; Brain SD
    Br J Pharmacol; 2000 Aug; 130(7):1589-96. PubMed ID: 10928962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A calcitonin gene-related peptide (CGRP) antagonist (CGRP8-37) inhibits microvascular responses induced by CGRP and capsaicin in skin.
    Hughes SR; Brain SD
    Br J Pharmacol; 1991 Nov; 104(3):738-42. PubMed ID: 1797334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Laser Doppler spectral analysis of patients with Raynaud's phenomenon during a standardized thermal test].
    Léger P
    Ann Dermatol Venereol; 1998 Nov; 125 Suppl 2():S28-9. PubMed ID: 9922888
    [No Abstract]   [Full Text] [Related]  

  • 39. Arteriolar resistance and hemorheological disorders related to Raynaud's phenomenon.
    Mchedlishvili G; Mantskava M; Pargalava N
    Microvasc Res; 2001 Sep; 62(2):190-5. PubMed ID: 11516248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of topically applied hexyl nicotinate lotion on the cutaneous blood flow in patients with Raynaud's phenomenon.
    Bunker CB; Lanigan S; Rustin MH; Dowd PM
    Br J Dermatol; 1988 Dec; 119(6):771-6. PubMed ID: 3203071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.